MedPath

CHRISTENSEN MIKKEL

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:4

Trial Phases

2 Phases

Early Phase 1:1
Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (75.0%)
Early Phase 1
1 (25.0%)

Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes

Not Applicable
Completed
Conditions
Type 1 Diabetes Mellitus
First Posted Date
2017-06-22
Last Posted Date
2017-06-23
Lead Sponsor
Mikkel Christensen
Target Recruit Count
10
Registration Number
NCT03195257

Liraglutide in Spinal Fluid

Not Applicable
Completed
Conditions
Liraglutide Blood-brain Transfer
First Posted Date
2014-04-04
Last Posted Date
2014-04-04
Lead Sponsor
Mikkel Christensen
Target Recruit Count
8
Registration Number
NCT02104037
Locations
🇩🇰

Diabetes Research Division, Department of Medicine, Hellerup, Denmark

GIP and GLP-1 in Type 1 Diabetes

Not Applicable
Completed
Conditions
Hypoglycemia
First Posted Date
2012-12-03
Last Posted Date
2015-07-13
Lead Sponsor
Mikkel Christensen
Target Recruit Count
10
Registration Number
NCT01739283
Locations
🇩🇰

Gentofte Hospital, Hellerup, Denmark

GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes

Early Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
First Posted Date
2011-08-11
Last Posted Date
2013-04-02
Lead Sponsor
Mikkel Christensen
Target Recruit Count
12
Registration Number
NCT01414556
Locations
🇩🇰

Gentofte Hospital, Hellerup, Denmark

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.